2017 Press Releases Keyword Search Year: 20202019201820172016201520142013 Jun 3, 2019 Summary ToggleAgios Presents Updated Data from Phase 1 Studies of TIBSOVO® (ivosidenib) in Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy May 15, 2019 Summary ToggleAgios to Present Clinical Data from its IDH Program at ASCO May 15, 2019 Summary ToggleAgios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients May 2, 2019 Summary ToggleAgios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO® as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy May 2, 2019 Summary ToggleAgios Reports Business Highlights and First Quarter 2019 Financial Results Apr 25, 2019 Summary ToggleAgios to Webcast Conference Call of First Quarter 2019 Financial Results on May 2, 2019 Apr 2, 2019 Summary ToggleAgios Announces New Commercial Leadership Structure Mar 26, 2019 Summary ToggleAgios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy Mar 4, 2019 Summary ToggleAgios to Present at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019 Feb 25, 2019 Summary ToggleAgios Reports Updated Data from Phase 1 Study of Ivosidenib in Combination with Azacitidine Demonstrating Deep and Durable Responses in Newly Diagnosed IDH1 Mutant Acute Myeloid Leukemia (AML) Patients Feb 21, 2019 Summary ToggleAgios to Present at the Leerink Global Healthcare Conference on Thursday, February 28, 2019 Feb 20, 2019 Summary ToggleAgios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy Feb 14, 2019 Summary ToggleAgios Reports Fourth Quarter and Full Year 2018 Financial Results Jan 31, 2019 Summary ToggleAgios to Webcast Conference Call of Fourth Quarter and Full Year 2018 Financial Results on February 14, 2019 Jan 7, 2019 Summary ToggleAgios Highlights Key 2019 Initiatives to Broaden Potential for Cancer and Rare Genetic Disease Programs to Build Long-Term Value Dec 28, 2018 Summary ToggleAgios to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 Dec 3, 2018 Summary ToggleAgios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Standard Treatment and Myelodysplastic Syndrome (MDS) Dec 3, 2018 Summary ToggleAgios Announces Updated Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed AML Patients With an IDH Mutation Nov 16, 2018 Summary ToggleAgios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma Nov 1, 2018 Summary ToggleAgios to Present Updated Clinical Data at the 2018 ASH Annual Meeting Nov 1, 2018 Summary ToggleAgios Reports Third Quarter 2018 Financial Results Oct 18, 2018 Summary ToggleAgios to Webcast Conference Call of Third Quarter 2018 Financial Results on November 1, 2018 Sep 4, 2018 Summary ToggleAgios Announces Chief Executive Officer Succession Plan Aug 28, 2018 Summary ToggleAgios to Present at the Citi 13th Annual Biotech Conference Wednesday, September 5, 2018 Aug 2, 2018 Summary ToggleAgios Reports Second Quarter 2018 Financial Results Jul 23, 2018 Summary ToggleAgios to Webcast Conference Call of Second Quarter 2018 Financial Results on August 2, 2018 Jul 20, 2018 Summary ToggleFDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation Jun 26, 2018 Summary ToggleAgios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China Jun 18, 2018 Summary ToggleAgios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused Jun 4, 2018 Summary ToggleNew Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients Jun 2, 2018 Summary ToggleUpdated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent Jun 1, 2018 Summary ToggleAgios Presents Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma and Other Solid Tumors May 16, 2018 Summary ToggleAgios to Present New Clinical Data from its IDH Programs at ASCO May 4, 2018 Summary ToggleAgios Provides Business Update on Discovery Research Strategy and Pipeline, Progress on Clinical Programs, Commercial Launch Preparations and Reports First Quarter 2018 Financial Results at Investor Day Apr 27, 2018 Summary ToggleAgios Announces Revised Starting Time of 8:00am ET for Investor Day and First Quarter 2018 Financial Results Webcast on Friday, May 4, 2018 Apr 11, 2018 Summary ToggleAgios to Webcast Investor Day and First Quarter 2018 Financial Results on Friday, May 4, 2018 Mar 19, 2018 Summary ToggleAgios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or Lymphoma with an MTAP Deletion Mar 5, 2018 Summary ToggleAgios to Present at the Cowen 38th Annual Healthcare Conference Monday, March 12, 2018 Feb 15, 2018 Summary ToggleFDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation Feb 14, 2018 Summary ToggleAgios Reports Fourth Quarter and Full Year 2017 Financial Results Jan 31, 2018 Summary ToggleAgios to Webcast Conference Call of Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018 Jan 23, 2018 Summary ToggleAgios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares Jan 18, 2018 Summary ToggleAgios Announces Pricing of $475 Million Public Offering of Common Stock Jan 17, 2018 Summary ToggleAgios Announces Proposed Offering of Common Stock Jan 8, 2018 Summary ToggleAgios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to Drive Long Term Value Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last